Definition of pain amended after four decades
The International Association for the Study of Pain
(IASP) Council earlier in 1979 defined pain as "an unpleasant sensory
and emotional experience associated with actual or potential tissue
damage, or described in terms of such damage." This definition had
long been condemned for disregarding the heterogeneity of mind-body
interactions, ignoring ‘the ethical dimensions of pain’, inadequately
addressing pain in disempowered and neglected populations (neonates and
elderly), belittling severe pain, and suffering associated with many
diseases and excluding cognitive and social aspects inherent to the
experience of pain.
The IASP felt the need for an unambiguous and concise
definition to provide those dealing with pain with a shared
understanding of the term to apply to health policy, research, and
clinical care. A 14-member, multinational multidisciplinary Task Force
updated the definition which was unanimously accepted by the IASP
Council early in 2020. The revised definition is: "an unpleasant
sensory and emotional experience associated with, or resembling that
associated with, actual or potential tissue damage." The definition
also includes the "etymology of the word pain" and "six notes" that
highlight the need to assess the untoward effects of pain on an
individual’s function, social and psychological well-being to help
personalize their management.
The goal was to redefine pain in broad terms, in tune
with the latest understanding of various factors that possibly
contribute to the experience of pain, in hope that a better
understanding of the nuances and the complexity of pain could result in
better assessment and management of those with pain. A key amendment is
replacing the terminology that relied upon a patient’s capacity to
describe the experience to qualify as pain. The revised definition gives
more room and respect for self-report by underscoring that tissue damage
is not required.
(Pain July 2020)
Support breastfeeding for a healthier planet
Since 1992, the first week of August has been
celebrated globally as the World Breastfeeding Week. The theme
this year is ‘Support breastfeeding for a healthier planet.’ The main
objectives as per the Breastfeeding Promotion Network of India are to
generate awareness and action on the deleterious effects of breast milk
substitutes (BMS) and the protective role of breastfeeding on the
environment and to involve groups for advocacy in different states to
improve protection, promotion, and support of breastfeeding.
Breastfeeding safeguards the environment and is a
climate-friendly and environmentally sustainable method of feeding. On
the other hand, the use of BMS generates greenhouse gases in the
production process and waste in the form of bottles, teats, tin
containers, and promotional material, imposing further burden on the
planet. The sale of BMS is increasing rapidly despite the myriad
advantages of breastfeeding. The total sale of BMS in India was 26,900
tons in 2016 with an estimated sale of 30,700 tons in 2021 (a 14%
cumulative increase). Herculean efforts are needed to reduce its
consumption and augment breastfeeding rates through good support systems
for mothers.
WHO and UNICEF have called on governments to protect
and foster mothers’ access to skilled breastfeeding counseling that can
empower women to overcome obstacles and prevent practices interfering
with optimal breastfeeding, such as the provision of BMS. Amidst the
COVID-19 pandemic, it is necessary to ensure that mothers obtain the
breastfeeding counselling they need.
(www.bpni.org July 2020, www.who.int 31 July 2020)
A game changer in COVID-19 testing
Testing for SARS-CoV-2 has been a major deterrent in
our battle against COVID-19, with protracted delays and dearth of kits
and reagents. In what could be a ground-breaking diagnostic innovation,
the US FDA authorized the emergency use of a rapid, inexpensive,
non-invasive saliva-based test, called Saliva Direct on August 15, 2020.
Developed at Yale’s School of Public Health,
SalivaDirect uses saliva instead of nasopharyngeal samples, permitting
non-invasive frequent sampling. Saliva can be self-collected in any
sterile container, mitigating the need for special swabs, collection
devices and trained healthcare professionals. This dualplex quantitative
reverse transcription PCR assay does not require a preservative or the
time-consuming and expensive nucleic acid extraction process. The
ability to perform the test without these kits intensifies the capacity
for increased testing, while making it less resource dependent. Another
key component is its validation with reagents and instruments from
multiple vendors, thereby minimizing risk for supply chain issues. It is
highly sensitive (88-94%) with a limit of detection of 6-12 copies/
mL.
Yale envisages providing theSalivaDirect protocol open source to
interested laboratories. As widespread testing is the key to containment
of the virus, this flexible and inexpensive test (about $10/sample) is a
viable and accessible option to help alleviate COVID-19 testing demands.
This test, coming at a time of intense pressure on
supplies and resources, could prove to be a turning point in our fight
against the virus.
(The Hindu 17 August 2020, MedRxiv preprint 4 August
2020)